

---

**Integrated Therapy for Mental and Behavioural Disorders Due to Use of Cannabinoids**

I. Sosin<sup>1</sup>, Y.U. Chuev<sup>1</sup>, E. Goncharova<sup>1</sup>

<sup>1</sup>Narcology, Kharkov medical academy of postgraduate education, Kharkov, Ukraine

---

High prevalence of mental and behavioural disorders at cannabinoid pathological dependence in population, high risk of comorbid diseases development, absence of effective methods for pathogenetic treatment determine topicality of this addictive disease.

Currently, specific clinical manifestations of discontinuation syndrome, changed reactivity (tolerance), different somatic vegetative disorders, presence of subject dreams, pathognomonic liver lesions are important clinical markers of hashish dependence. Impulse actualization periods are accompanied with functional deviations in cerebral haemodynamics as pathophysiological ground for abstinent disorders and recurrences of the disease.

We have elaborated and tested in 35 cannabinoid addicts the integrated treatment algorithm which combines: 1) stopping of cessation syndrome with detoxication membrane plasmapheresis and plasma exfusion of 800-1000 ml, course of 2-3 procedures; 2) using new generation hepatoprotectors "L'esfal" (5.0 ml intravenously, once daily, 5-10 injections course) and "Antral" (0.2 g tablets per orally 3 times daily, 3-4-week course); 3) anticraving method with innovative autotraining computer system with biofeedback – psychophysiological bio-adaptive system regulation: 7-10 sessions during which the patient uses special training recommendations in autoregulation of physiological and pathologically changed body functions and acquires the skills of independent suppression of cannabinoid smoking addiction; 4) psychotherapeutic mediation procedure for the present visual signs of toxic metabolic (xenobiotic) post-intoxication contamination of plasma excreted and collected at plasmapheresis aimed to target anticraving of respondent's cognitive frustration.

Method was carried out to minimize background standard symptomatic pharmacotherapy. High efficiency of the proposed complex has been proved on the ground of clinical psychopathological, pathopsychological testing, computed electroencephalography and rheoencephalography as well as biochemical studies.